People · Operator
Named in public records as an officer, director or promoter · active 2009–2021 · Biotechnology, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Amicus Therapeutics, Inc. | — | Biotechnology | Series D+ | $314.5M | $420.8M | 2012 |
| REGENXBIO Inc. | — | Biotechnology | Series C | $105.9M | $2.9B | 2015 |
| Dimension Therapeutics, Inc. | — | Other Technology | Series C | $94.5M | $2.0B | 2015 |
| WindMIL Therapeutics, Inc. | — | Biotechnology | Series B | $44.9M | $72.5M | 2021 |
| Nora Therapeutics, Inc. | — | Biotechnology | Series B | $38.3M | $39.7M | 2009 |
Donald J. Hayden, Jr. at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Donald J. Hayden, Jr. on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Donald J Hayden | 2 | 3 |
| Rishi Gupta | 1 | 12 |
| Brian Halak | 1 | 10 |
| Annalisa Jenkins | 1 | 8 |
| David Clark | 1 | 8 |
| P. Sherrill Neff | 1 | 8 |
| Brian Dovey | 1 | 7 |
| Thomas Beck | 1 | 7 |
| Chen Yu | 1 | 7 |
| David Schnell | 1 | 7 |
| Sol J. Barer | 1 | 6 |
| Ted W. Love | 1 | 5 |
| Bradley Campbell | 1 | 5 |
| James N. Topper | 1 | 5 |
| Jay K. Hachigian | 1 | 5 |
| Donald Hayden | 1 | 3 |
| Michael A. Kelly | 1 | 3 |
| John Daniel Kiser | 1 | 3 |
| Allan M. Fox | 1 | 3 |
| Donald Hayden, Jr. | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.